AVASTIN Concentrate for solution for infusion Ref.[6495] Active ingredients: Bevacizumab

Source: European Medicines Agency (EU)  Revision Year: 2018  Publisher: Roche Registration GmbH, Emil-Barell-Strasse 1, 79639, Grenzach-Wyhlen, Germany

Pharmacodynamic properties

Pharmacotherapeutic group: antineoplastic and immunomodulating agents, antineoplastic agents, other antineoplastic agents, monoclonal antibodies
ATC code: L01XC07

Mechanism of action

Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.

Pharmacodynamic effects

Administration of bevacizumab or its parental murine antibody to xenotransplant models of cancer in nude mice resulted in extensive anti-tumour activity in human cancers, including colon, breast, pancreas and prostate. Metastatic disease progression was inhibited and microvascular permeability was reduced.

Clinical efficacy

Metastatic carcinoma of the colon or rectum (mCRC)

The safety and efficacy of the recommended dose (5 mg/kg of body weight every two weeks) in metastatic carcinoma of the colon or rectum were studied in three randomised, active-controlled clinical trials in combination with fluoropyrimidine-based first-line chemotherapy. Avastin was combined with two chemotherapy regimens:

  • AVF2107g: A weekly schedule of irinotecan/bolus 5-fluorouracil/folinic acid (IFL) for a total of 4 weeks of each 6 week-cycle (Saltz regimen).
  • AVF0780g: In combination with bolus 5-fluorouracil/folinic acid (5-FU/FA) for a total of 6 weeks of each 8 week-cycle (Roswell Park regimen).
  • AVF2192g: In combination with bolus 5-FU/FA for a total of 6 weeks of each 8 week-cycle (Roswell Park regimen) in patients who were not optimal candidates for first-line irinotecan treatment.

Three additional studies with bevacizumab have been conducted in mCRC patients: first-line (NO16966), second-line with no previous bevacizumab treatment (E3200), and second-line with previous bevacizumab treatment following disease progression in first-line (ML18147). In these studies, bevacizumab was administered at the following dosing regimens in combination with FOLFOX-4 (5-FU/LV/oxaliplatin), XELOX (capecitabine/oxaliplatin), and fluoropyrimidine/irinotecan and fluoropyrimidine/oxaliplatin:

  • NO16966: Avastin 7.5 mg/kg of body weight every 3 weeks in combination with oral capecitabine and intravenous oxaliplatin (XELOX) or Avastin 5 mg/kg every 2 weeks in combination with leucovorin plus 5-fluorouracil bolus, followed by 5-fluorouracil infusion, with intravenous oxaliplatin (FOLFOX-4).
  • E3200: Avastin 10 mg/kg of body weight every 2 weeks in combination with leucovorin and 5-fluorouracil bolus, followed by 5-fluorouracil infusion, with intravenous oxaliplatin (FOLFOX-4) in bevacizumab-naïve patients.
  • ML18147: Avastin 5.0 mg/kg of body weight every 2 weeks or Avastin 7.5 mg/kg of body weight every 3 weeks in combination with fluoropyrimidine/irinotecan or fluoropyrimidine/oxaliplatin in patients with disease progression following first-line treatment with bevacizumab. Use of irinotecan- or oxaliplatin-containing regimen was switched depending on first-line usage of either oxaliplatin or irinotecan.

AVF2107g:

This was a phase III randomised, double-blind, active-controlled clinical trial evaluating Avastin in combination with IFL as first-line treatment for metastatic carcinoma of the colon or rectum. Eight hundred and thirteen patients were randomised to receive IFL + placebo (Arm 1) or IFL + Avastin (5 mg/kg every 2 weeks, Arm 2). A third group of 110 patients received bolus 5-FU/FA + Avastin (Arm 3). Enrolment in Arm 3 was discontinued, as pre-specified, once safety of Avastin with the IFL regimen was established and considered acceptable. All treatments were continued until disease progression. The overall mean age was 59.4 years; 56.6% of patients had an ECOG performance status of 0, 43% had a value of 1 and 0.4% had a value of 2. 15.5% had received prior radiotherapy and 28.4% prior chemotherapy.

The primary efficacy variable of the trial was overall survival. The addition of Avastin to IFL resulted in statistically significant increases in overall survival, progression-free survival and overall response rate (see Table 4). The clinical benefit, as measured by overall survival, was seen in all pre-specified patient subgroups, including those defined by age, sex, performance status, location of primary tumour, number of organs involved and duration of metastatic disease.

The efficacy results of Avastin in combination with IFL-chemotherapy are displayed in Table 4.

Table 4. Efficacy results for trial AVF2107g:

 AVF2107g
Arm 1 IFL + placeboArm 2 IFL + Avastina
Number of patients411402
Overall survival
Median time (months) 15.620.3
95% CI14.29–16.9918.46–24.18
Hazard ratiob0.660 (p-value=0.00004)
Progression-free survival
Median time (months) 6.210.6
Hazard ratio0.54 (p-value<0.0001)
Overall response rate
Rate (%)34.844.8
 (p-value=0.0036)  

a 5 mg/kg every 2 weeks.
b Relative to control arm.

Among the 110 patients randomised to Arm 3 (5-FU/FA + Avastin) prior to discontinuation of this arm, the median overall survival was 18.3 months and the median progression free survival was 8.8 months.

AVF2192g:

This was a phase II randomised, double-blind, active-controlled clinical trial evaluating the efficacy and safety of Avastin in combination with 5-FU/FA as first-line treatment for metastatic colorectal cancer in patients who were not optimal candidates for first-line irinotecan treatment. One hundred and five patients were randomised to 5-FU/FA + placebo arm and 104 patients to 5-FU/FA + Avastin (5 mg/kg every 2 weeks) arm. All treatments were continued until disease progression. The addition of Avastin 5 mg/kg every two weeks to 5-FU/FA resulted in higher objective response rates, significantly longer progression-free survival, and a trend in longer survival as compared to 5-FU/FA chemotherapy alone.

AVF0780g:

This was a phase II randomised, active-controlled, open-labelled clinical trial investigating Avastin in combination with 5-FU/FA as first-line treatment of metastatic colorectal cancer. The median age was 64 years. 19% of the patients had received prior chemotherapy and 14% prior radiotherapy. Seventy-one patients were randomised to receive bolus 5-FU/FA or 5-FU/FA + Avastin (5 mg/kg every 2 weeks). A third group of 33 patients received bolus 5-FU/FA + Avastin (10 mg/kg every 2 weeks). Patients were treated until disease progression. The primary endpoints of the trial were objective response rate and progression-free survival. The addition of Avastin 5 mg/kg every two weeks to 5-FU/FA resulted in higher objective response rates, longer progression-free survival, and a trend in longer survival, compared with 5-FU/FA chemotherapy alone (see Table 5). These efficacy data are consistent with the results from trial AVF2107g.

The efficacy data from trials AVF0780g and AVF2192g investigating Avastin in combination with 5-FU/FA-chemotherapy are summarised in Table 5.

Table 5. Efficacy results for trials AVF0780g and AVF2192g:

 AVF0780gAVF2192g
5-FU/FA5-FU/FA + Avastin a5-FU/FA + Avastin b5-FU/FA + placebo5-FU/FA + Avastin
Number of patients363533105104
Overall survival
Median time (months) 13.617.715.212.916.6
95% CI   10.35-16.9513.63-19.32
Hazard ratioc- 0.521.01 0.79
p-value 0.0730.978 0.16
Progression-free survival
Median time (months)5.29.07.25.59.2
Hazard ratio 0.440.69 0.5
p-value- 0.00490.217 0.0002
Overall response rate
Rate (percent)16.740.024.215.226
95% CI7.0−33.524.4−57.811.7-42.69.2-23.918.1-35.6
p-value 0.0290.43 0.055
Duration of response
Median time (months) NR9.35.06.89.2
25–75 percentile (months) 5.5−NR6.1−NR3.8–7.85.59-9.175.88-13.01

a 5 mg/kg every 2 weeks.
b 10 mg/kg every 2 weeks.
c Relative to control arm.
NR = not reached.

NO16966:

This was a phase III randomised, double-blind (for bevacizumab), clinical trial investigating Avastin 7.5 mg/kg in combination with oral capecitabine and IV oxaliplatin (XELOX), administered on a 3-weekly schedule; or Avastin 5 mg/kg in combination with leucovorin with 5-fluorouracil bolus, followed by 5-fluorouracil infusional, with IV oxaliplatin (FOLFOX-4), administered on a 2-weekly schedule. The trial contained two parts: an initial unblinded 2-arm part (Part I) in which patients were randomised to two different treatment groups (XELOX and FOLFOX-4) and a subsequent 2 × 2 factorial 4-arm part (Part II) in which patients were randomised to four treatment groups (XELOX + placebo, FOLFOX-4 + placebo, XELOX + Avastin, FOLFOX-4 + Avastin). In Part II, treatment assignment was double-blind with respect to Avastin.

Approximately 350 patients were randomised into each of the 4 trial arms in the Part II of the trial.

Table 6. Treatment regimens in trial NO16966 (mCRC):

The primary efficacy parameter of the trial was the duration of progression-free survival. In this trial, there were two primary objectives: to show that XELOX was non-inferior to FOLFOX-4 and to show that Avastin in combination with FOLFOX-4 or XELOX chemotherapy was superior to chemotherapy alone. Both co-primary objectives were met:

  • Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4-containing arms in the overall comparison was demonstrated in terms of progression-free survival and overall survival in the eligible per-protocol population.
  • Superiority of the Avastin-containing arms versus the chemotherapy alone arms in the overall comparison was demonstrated in terms of progression-free survival in the ITT population (Table 7).

Secondary PFS analyses, based on ‘on-treatment’-based response assessments, confirmed the significantly superior clinical benefit for patients treated with Avastin (analyses shown in Table 7), consistent with the statistically significant benefit observed in the pooled analysis.

Table 7. Key efficacy results for the superiority analysis (ITT population, trial NO16966):

Endpoint (months) FOLFOX-4 or XELOX + placebo (n=701) FOLFOX-4 or XELOX + bevacizumab (n=699) P-value
Primary endpoint
Median PFS**8.09.40.0023
Hazard ratio (97.5% CI)a 0.83 (0.72–0.95) 
Secondary endpoints
Median PFS (on treatment)**7.910.4<0.0001
Hazard ratio (97.5% CI) 0.63 (0.52-0.75)  
Overall response rate (invest. assessment)** 49.2%46.5% 
Median overall survival*19.921.20.0769
Hazard ratio (97.5% CI)0.89 (0.76-1.03) 

* Overall survival analysis at clinical cut-off 31 January 2007
** Primary analysis at clinical cut-off 31 January 2006
a relative to control arm

In the FOLFOX treatment subgroup, the median PFS was 8.6 months in placebo and 9.4 months in bevacizumab treated patients, HR =0.89, 97.5% CI =[0.73; 1.08]; p-value=0.1871, the corresponding results in the XELOX treatment subgroup being 7.4 vs. 9.3 months, HR =0.77, 97.5% CI =[0.63; 0.94] p-value=0.0026.

The median overall survival was 20.3 months in placebo and 21.2 months in bevacizumab treated patients in the FOLFOX treatment subgroup, HR =0.94, 97.5% CI =[0.75; 1.16]; p-value=0.4937, the corresponding results in the XELOX, treatment subgroup being 19.2 vs. 21.4 months, HR =0.84, 97.5% CI =[0.68; 1.04]; p-value=0.0698.

ECOG E3200:

This was a phase III randomised, active-controlled, open-label trial investigating Avastin 10 mg/kg in combination with leucovorin with 5-fluorouracil bolus and then 5-fluorouracil infusional, with IV oxaliplatin (FOLFOX-4), administered on a 2-weekly schedule in previously-treated patients (second line) with advanced colorectal cancer. In the chemotherapy arms, the FOLFOX-4 regimen used the same doses and schedule as shown in Table 6 for trial NO16966.

The primary efficacy parameter of the trial was overall survival, defined as the time from randomisation to death from any cause. Eight hundred and twenty-nine patients were randomised (292 FOLFOX-4, 293 Avastin + FOLFOX-4 and 244 Avastin monotherapy). The addition of Avastin to FOLFOX-4 resulted in a statistically significant prolongation of survival. Statistically significant improvements in progression-free survival and objective response rate were also observed (see Table 8).

Table 8. Efficacy results for trial E3200:

 E3200
FOLFOX-4FOLFOX-4 + Avastina
Number of patients292293
Overall survival
Median (months)10.813.0
95% CI10.12–11.8612.09–14.03
Hazard ratiob0.751 (p-value=0.0012)
Progression-free survival
Median (months)4.57.5
Hazard ratio0.518 (p-value<0.0001)
Objective response rate
Rate8.6%22.2%
 (p-value<0.0001)  

a 10 mg/kg every 2 weeks
b Relative to control arm

No significant difference was observed in the duration of overall survival between patients who received Avastin monotherapy compared to patients treated with FOLFOX-4. Progression-free survival and objective response rate were inferior in the Avastin monotherapy arm compared to the FOLFOX-4 arm.

ML18147:

This was a Phase III randomised, controlled, open-label trial investigating Avastin 5.0 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination with fluoropyrimidine-based chemotherapy versus fluoropyrimidine-based chemotherapy alone in patients with mCRC who have progressed on a first- line bevacizumab-containing regimen.

Patients with histologically confirmed mCRC and disease progression were randomised 1:1 within 3 months after discontinuation of bevacizumab first-line therapy to receive fluoropyrimidine/oxaliplatin- or fluoropyrimidine/irinotecan-based chemotherapy (chemotherapy switched depending on first-line chemotherapy) with or without bevacizumab. Treatment was given until progressive disease or unacceptable toxicity. The primary outcome measure was overall survival defined as the time from randomisation until death from any cause.

A total of 820 patients were randomised. The addition of bevacizumab to fluoropyrimidine-based chemotherapy resulted in a statistically significant prolongation of survival in patients with mCRC who have progressed on a first-line bevacizumab-containing regimen (ITT = 819) (see Table 9).

Table 9. Efficacy Results for Study ML18147 (ITT population):

 ML18147
 fluoropyrimidine/irinotecan or fluoropyrimidine/oxaliplatin based chemotherapyfluoropyrimidine/irinotecan or fluoropyrimidine/oxaliplatin based chemotherapy + Avastina
Number of Patients410409
Overall Survival
Median (months) 9.811.2
Hazard ratio (95% confidence interval) 0.81 (0.69, 0.94) (p-value=0.0062)
Progression-Free Survival
Median (months) 4.15.7
Hazard ratio (95% confidence interval) 0.68 (0.59, 0.78) (p-value<0.0001)
Objective Response Rate (ORR)
Patients included in analysis406404
Rate3.9%5.4%
 (p-value = 0.3113)

a 5.0 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks

Statistically significant improvements in progression-free survival were also observed. Objective response rate was low in both treatment arms and the difference was not significant.

Study E3200 used a 5 mg/kg/week equivalent dose of bevacizumab in bevacizumab-naïve patients, while study ML18147 used a 2.5 mg/kg/week equivalent dose of bevacizumab in bevacizumab- pretreated patients. A cross-trial comparison of the efficacy and safety data is limited by differences between these studies, most notably in patient populations, previous bevacizumab exposure and chemotherapy regimens. Both the 5 mg/kg/week and 2.5 mg/kg/week equivalent doses of bevacizumab provided a statistically significant benefit with regards to OS (HR 0.751 in study E3200; HR 0.81 in study ML18147) and PFS (HR 0.518 in study E3200; HR 0.68 in study ML18147). In terms of safety, there was a higher overall incidence of Grade 3-5 AEs in study E3200 relative to study ML18147.

Metastatic breast cancer (mBC)

Two large Phase III trials were designed to investigate the treatment effect of Avastin in combination with two individual chemotherapy agents, as measured by the primary endpoint of PFS. A clinically meaningful and statistically significant improvement in PFS was observed in both trials.

Summarised below are PFS results for the individual chemotherapy agents included in the indication:

  • Study E2100 (paclitaxel)
    • Median PFS increase 5.6 months, HR 0.421 (p<0.0001, 95% CI 0.343; 0.516)
  • Study AVF3694g (capecitabine)
    • Median PFS increase 2.9 months, HR 0.69 (p=0.0002, 95% CI 0.56; 0.84)

Further details of each study and the results are provided below.

ECOG E2100:

Trial E2100 was an open-label, randomised, active controlled, multicentre clinical trial evaluating Avastin in combination with paclitaxel for locally recurrent or metastatic breast cancer in patients who had not previously received chemotherapy for locally recurrent and metastatic disease. Patients were randomised to paclitaxel alone (90 mg/m 2 IV over 1 hour once weekly for three out of four weeks) or in combination with Avastin (10 mg/kg IV infusion every two weeks). Prior hormonal therapy for the treatment of metastatic disease was allowed. Adjuvant taxane therapy was allowed only if it was completed at least 12 months prior to trial entry. Of the 722 patients in the trial, the majority of patients had HER2-negative disease (90%), with a small number of patients with unknown (8%) or confirmed HER2-positive status (2%), who had previously been treated with or were considered unsuitable for trastuzumab therapy. Furthermore, 65% of patients had received adjuvant chemotherapy including 19% prior taxanes and 49% prior anthracyclines. Patients with central nervous system metastases, including previously treated or resected brain lesions, were excluded.

In trial E2100, patients were treated until disease progression. In situations where early discontinuation of chemotherapy was required, treatment with Avastin as a single agent continued until disease progression. The patient characteristics were similar across the trial arms. The primary endpoint of this trial was progression free survival (PFS), based on trial investigators' assessment of disease progression. In addition, an independent review of the primary endpoint was also conducted. The results of this trial are presented in Table 10.

Table 10. Trial E2100 efficacy results:

Progression-free survival
 Investigator assessment*IRF assessment
 Paclitaxel (n=354) Paclitaxel/Avastin (n=368) Paclitaxel (n=354) Paclitaxel/Avastin (n=368)
Median PFS (months)5.811.45.811.3
HR (95% CI)0.421 (0.343; 0.516) 0.483 (0.385; 0.607)
p-value<0.0001<0.0001
Response rates (for patients with measurable disease)
 Investigator assessmentIRF assessment
 Paclitaxel (n=273) Paclitaxel/Avastin (n=252) Paclitaxel (n=243) Paclitaxel/Avastin (n=229)
% pts with objective response23.448.022.249.8
p-value<0.0001<0.0001
Overall survival
 Paclitaxel (n=354) Paclitaxel/Avastin (n=368)
Median OS (months) 24.826.5
HR (95% CI) 0.869 (0.722; 1.046)
p-value0.1374

* primary analysis

The clinical benefit of Avastin as measured by PFS was seen in all pre-specified subgroups tested (including disease-free interval, number of metastatic sites, prior receipt of adjuvant chemotherapy and oestrogen receptor (ER) status).

AVF3694g:

Study AVF3694g was a Phase III, multicentre, randomised, placebo-controlled trial designed to evaluate the efficacy and safety of Avastin in combination with chemotherapy compared to chemotherapy plus placebo as first-line treatment for patients with HER2-negative metastatic or locally recurrent breast cancer.

Chemotherapy was chosen at the investigator’s discretion prior to randomisation in a 2:1 ratio to receive either chemotherapy plus Avastin or chemotherapy plus placebo. The choices of chemotherapy included capecitabine, taxane (protein-bound paclitaxel, docetaxel), and anthracycline-based agents (doxorubicin/cyclophosphamide, epirubicin/cyclophosphamide, 5-fluorouracil/doxorubicin/cyclophosphamide, 5-fluorouracil/epirubicin/cyclophosphamide) given every three weeks (q3w). Avastin or placebo was administered at a dose of 15 mg/kg q3w.

This study included a blinded treatment phase, an optional open-label post-progression phase, and a survival follow-up phase. During the blinded treatment phase, patients received chemotherapy and medicinal product (Avastin or placebo) every 3 weeks until disease progression, treatment-limiting toxicity, or death. On documented disease progression, patients who entered the optional open-label phase could receive open-label Avastin together with a wide-range of second line therapies.

Statistical analyses were performed independently for 1) patients who received capecitabine in combination with Avastin or placebo; 2) patients who received taxane-based or anthracycline-based chemotherapy in combination with Avastin or placebo. The primary endpoint of the study was PFS by investigator assessment. In addition, the primary endpoint was also assessed by an independent review committee (IRC).

The results of this study from the final protocol defined analyses for progression free survival and response rates for the independently powered capecitabine cohort of Study AVF3694g are presented in Table 11 Results from an exploratory overall survival analysis which include an additional 7 months of follow-up (approximately 46% of patients had died) are also presented. The percentage of patients who received Avastin in the open-label phase was 62.1% in the capecitabine + placebo arm and 49.9% in the capecitabine + Avastin arm.

Table 11. Efficacy results for study AVF3694g: – Capecitabinea and Avastin/Placebo (Cap + Avastin/Pl):

Progression-free survivalb
 Investigator AssessmentIRC Assessment
 Cap + Pl (n=206) Cap + Avastin (n=409) Cap + Pl (n=206) Cap + Avastin (n=409)
Median PFS (months) 5.78.66.29.8
Hazard ratio vs placebo arm (95% CI) 0.69 (0.56; 0.84) 0.68 (0.54; 0.86)
p-value0.00020.0011
Response rate (for patients with measurable disease)b
 Cap + Pl (n=161) Cap + Avastin (n=325)
% pts with objective response23.635.4
p-value0.0097
Overall survivalb
HR (95% CI) 0.88 (0.69; 1.13)
p-value (exploratory) 0.33

a 1000 mg/m² oral twice daily for 14 days administered every 3 weeks
b Stratified analysis included all progression and death events except those where non-protocol therapy (NPT) was initiated prior to documented progression; data from those patients were censored at the last tumour assessment prior to starting NPT.

An unstratified analysis of PFS (investigator assessed) was performed that did not censor for non- protocol therapy prior to disease progression. The results of these analyses were very similar to the primary PFS results.

Non-small cell lung cancer (NSCLC)

First-line treatment of non-squamous NSCLC in combination with platinum-based chemotherapy

The safety and efficacy of Avastin, in addition to platinum-based chemotherapy, in the first-line treatment of patients with non-squamous non-small cell lung cancer (NSCLC), was investigated in trials E4599 and BO17704. An overall survival benefit has been demonstrated in trial E4599 with a 15 mg/kg/q3wk dose of bevacizumab. Trial BO17704 has demonstrated that both 7.5 mg/kg/q3wk and 15 mg/kg/q3wk bevacizumab doses increase progression free survival and response rate.

E4599:

E4599 was an open-label, randomised, active-controlled, multicentre clinical trial evaluating Avastin as first-line treatment of patients with locally advanced (stage IIIb with malignant pleural effusion), metastatic or recurrent NSCLC other than predominantly squamous cell histology.

Patients were randomised to platinum-based chemotherapy (paclitaxel 200 mg/m²) and carboplatin AUC =6.0, both by IV infusion (PC) on day 1 of every 3-week cycle for up to 6 cycles or PC in combination with Avastin at a dose of 15 mg/kg IV infusion day 1 of every 3-week cycle. After completion of six cycles of carboplatin-paclitaxel chemotherapy or upon premature discontinuation of chemotherapy, patients on the Avastin + carboplatin–paclitaxel arm continued to receive Avastin as a single agent every 3 weeks until disease progression. 878 patients were randomised to the two arms.

During the trial, of the patients who received trial treatment, 32.2% (136/422) of patients received 7-12 administrations of Avastin and 21.1% (89/422) of patients received 13 or more administrations of Avastin.

The primary endpoint was duration of survival. Results are presented in Table 12.

Table 12. Efficacy results for trial E4599:

 Arm 1. Carboplatin/PaclitaxelArm 2. Carboplatin/Paclitaxel + Avastin 15 mg/kg q 3 weeks
Number of patients444434
Overall survival
Median (months) 10.312.3
Hazard ratio0.80 (p=0.003) 95% CI (0.69; 0.93)
Progression-free survival
Median (months) 4.86.4
Hazard ratio
Overall response rate
Rate (percent) 12.929.0 (p<0.0001)

In an exploratory analysis, the extent of Avastin benefit on overall survival was less pronounced in the subgroup of patients who did not have adenocarcinoma histology.

BO17704:

Trial BO17704 was a randomised, double-blind phase III trial of Avastin in addition to cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with locally advanced (stage IIIb with supraclavicular lymph node metastases or with malignant pleural or pericardial effusion), metastatic or recurrent non-squamous NSCLC, who had not received prior chemotherapy. The primary endpoint was progression free survival, secondary endpoints for the trial included the duration of overall survival.

Patients were randomised to platinum-based chemotherapy, cisplatin 80 mg/m² intravenous infusion on day 1 and gemcitabine 1250 mg/m 2 intravenous infusion on days 1 and 8 of every 3-week cycle for up to 6 cycles (CG) with placebo or CG with Avastin at a dose of 7.5 or 15 mg/kg IV infusion day 1 of every 3-week cycle. In the Avastin-containing arms, patients could receive Avastin as a single-agent every 3 weeks until disease progression or unacceptable toxicity. Trial results show that 94% (277/296) of eligible patients went on to receive single agent bevacizumab at cycle 7. A high proportion of patients (approximately 62%) went on to receive a variety of non-protocol specified anti- cancer therapies, which may have impacted the analysis of overall survival.

The efficacy results are presented in Table 13.

Table 13. Efficacy results for trial BO17704:

 Cisplatin/Gemcitabine + placeboCisplatin/Gemcitabine + Avastin 7.5 mg/kg q 3 weeksCisplatin/Gemcitabine + Avastin 15 mg/kg q 3 weeks
Number of patients347345351
Progression-free survival
Median (months)6.16.7 (p=0.0026) 6.5 (p=0.0301)
Hazard ratio 0.75 [0.62; 0.91] 0.82 [0.68; 0.98]
Best overall response ratea
 20.1%34.1% (p<0.0001) 30.4% (p=0.0023)
Overall survival
Median (months)13.113.6 (p=0.4203) 13.4 (p=0.7613)
Hazard ratio 0.93 [0.78; 1.11] 1.03 [0.86, 1.23]

a patients with measurable disease at baseline

First-line treatment of non-squamous NSCLC with EGFR activating mutations in combination with erlotinib

JO25567:

Study JO25567 was a randomized, open-label, multi-center Phase II study conducted in Japan to evaluate the efficacy and safety of Avastin used in addition to erlotinib in patients with non-squamous NSCLC with EGFR activating mutations (exon 19 deletion or exon 21 L858R mutation) who had not received prior systemic therapy for Stage IIIB/IV or recurrent disease.

The primary endpoint was progression-free survival (PFS) based on independent review assessment. Secondary endpoints included overall survival, response rate, disease control rate, duration of response, and safety.

EGFR mutation status was determined for each patient prior to patient screening and 154 patients were randomised to receive either erlotinib + Avastin (erlotinib 150 mg oral daily + Avastin [15 mg/kg IV every 3 weeks]) or erlotinib monotherapy (150 mg oral daily) until disease progression (PD) or unacceptable toxicity. In the absence of PD, discontinuation of one component of study treatment in the erlotinib + Avastin arm did not lead to discontinuation of the other component of study treatment as specified in the study protocol.

The efficacy results of the study are presented in Table 14.

Table 14. Efficacy results for study JO25567:

 Erlotinib N=77#Erlotinib + Avastin N=75#
PFS^ (months)
Median9.716.0
HR (95% CI)0.54 (0.36; 0.79)
p-value0.0015
Overall Response Rate
Rate (n) 63.6% (49) 69.3% (52)
p-value0.4951
Overall Survival* (months)
Median48.548.4
HR (95% CI)0.91 (0.56; 1.46)
p-value0.6838

# A total of 154 patients (ECOG Performance Status 0 or 1) were randomized. However two of the randomized patients discontinued the study before receiving any study treatment
^ Blinded independent review (protocol-defined primary analysis)
* Exploratory analysis; OS updated analysis at clinical cut-off on 28 October 2015, approx. 45% patient had died and OS is therefore considered immature.
CI, confidence interval; HR, Hazard ratio from unstratified Cox regression analysis; NR, not reached.

Advanced and/or metastatic renal cell cancer (mRCC)

Avastin in combination with interferon alfa-2a for the first-line treatment of advanced and/ or metastatic renal cell cancer (BO17705)

This was a phase III randomised double-blind trial conducted to evaluate the efficacy and safety of Avastin in combination with interferon (IFN) alfa-2a versus IFN alfa-2a alone as first-line treatment in mRCC. The 649 randomised patients (641 treated) had Karnofsky Performance Status (KPS) of ≥70%, no CNS metastases and adequate organ function. Patients were nephrectomised for primary renal cell carcinoma. Avastin 10 mg/kg was given every 2 weeks until disease progression. IFN alfa-2a was given up to 52 weeks or until disease progression at a recommended starting dose of 9 MIU three times a week, allowing a dose reduction to 3 MIU three times a week in 2 steps. Patients were stratified according to country and Motzer score and the treatment arms were shown to be well balanced for the prognostic factors.

The primary endpoint was overall survival, with secondary endpoints for the trial including progression-free survival. The addition of Avastin to IFN-alpha-2a significantly increased PFS and objective tumour response rate. These results have been confirmed through an independent radiological review. However, the increase in the primary endpoint of overall survival by 2 months was not significant (HR= 0.91). A high proportion of patients (approximately 63% IFN/placebo; 55% Avastin/IFN) received a variety of non-specified post-trial anti-cancer therapies, including antineoplastic agents, which may have impacted the analysis of overall survival.

The efficacy results are presented in Table 15

Table 15. Efficacy results for trial BO17705:

 BO17705
Placebo + IFNaBvb + IFNa
Number of patients322327
Progression-free survival
Median (months) 5.410.2
Hazard ratio0.63
95% CI0.52, 0.75 (p-value<0.0001)
Objective response rate (%) in Patients with measurable disease
N289306
Response rate12.8%31.4%
 (p-value<0.0001)
Overall survival
Median (months)21.323.3
Hazard ratio0.91
95% CI0.76, 1.10 (p-value 0.3360)

a Interferon alfa-2a 9 MIU 3x/week
b Bevacizumab 10 mg/kg q 2 wk

An exploratory multivariate Cox regression model using backward selection indicated that the following baseline prognostic factors were strongly associated with survival independent of treatment: gender, white blood cell count, platelets, body weight loss in the 6 months prior to trial entry, number of metastatic sites, sum of longest diameter of target lesions, Motzer score. Adjustment for these baseline factors resulted in a treatment hazard ratio of 0.78 (95% CI [0.63; 0.96], p=0.0219), indicating a 22% reduction in the risk of death for patients in the Avastin + IFN alfa-2a arm compared to IFN alfa-2a arm.

Ninety seven (97) patients in the IFN alfa-2a arm and 131 patients in the Avastin arm reduced the dose of IFN alfa-2a from 9 MIU to either 6 or 3 MIU three times a week as pre-specified in the protocol. Dose-reduction of IFN alfa-2a did not appear to affect the efficacy of the combination of Avastin and IFN alfa-2a based on PFS event free rates over time, as shown by a sub-group analysis. The 131 patients in the Avastin + IFN alfa-2a arm who reduced and maintained the IFN alfa-2a dose at 6 or 3 MIU during the trial, exhibited at 6, 12 and 18 months PFS event free rates of 73, 52 and 21% respectively, as compared to 61, 43 and 17% in the total population of patients receiving Avastin + IFN alfa-2a.

AVF2938:

This was a randomised, double-blind, phase II clinical trial investigating Avastin 10 mg/kg in a 2 weekly schedule with the same dose of Avastin in combination with 150 mg daily erlotinib, in patients with metastatic clear cell RCC. A total of 104 patients were randomised to treatment in this trial, 53 to Avastin 10 mg/kg every 2 weeks plus placebo and 51 to Avastin 10 mg/kg every 2 weeks plus erlotinib 150 mg daily. The analysis of the primary endpoint showed no difference between the Avastin + Placebo arm and the Avastin + Erlotinib arm (median PFS 8.5 versus 9.9 months). Seven patients in each arm had an objective response. The addition of erlotinib to bevacizumab did not result in an improvement in OS (HR = 1.764; p=0.1789), duration of objective response (6.7 vs 9.1 months) or time to symptom progression (HR = 1.172; p=0.5076).

AVF0890:

This was a randomised phase II trial conducted to compare the efficacy and safety of bevacizumab versus placebo. A total of 116 patients were randomised to receive bevacizumab 3 mg/kg every 2 weeks (n=39), 10 mg/kg every 2 weeks; (n=37), or placebo (n=40). An interim analysis showed there was a significant prolongation of the time to progression of disease in the 10 mg/kg group as compared with the placebo group (hazard ratio, 2.55; p<0.001). There was a small difference, of borderline significance, between the time to progression of disease in the 3 mg/kg group and that in the placebo group (hazard ratio, 1.26; p=0.053). Four patients had objective (partial) response, and all of these had received the 10 mg/kg dose bevacizumab; the ORR for the 10 mg/kg dose was 10%.

Epithelial ovarian, fallopian tube and primary peritoneal cancer

Front-line treatment of ovarian cancer

The safety and efficacy of Avastin in the front-line treatment of patients with epithelial ovarian, fallopian tube or primary peritoneal cancer were studied in two phase III trials (GOG-0218 and BO17707) that evaluated the effect of the addition of Avastin to carboplatin and paclitaxel compared to the chemotherapy regimen alone.

GOG-0218:

The GOG-0218 study was a phase III multicentre, randomised, double-blind, placebo-controlled, three arm study evaluating the effect of adding Avastin to an approved chemotherapy regimen (carboplatin and paclitaxel) in patients with advanced ( Stages IIIB, IIIC and IV according to FIGO staging version dated 1988) epithelial ovarian, fallopian tube or primary peritoneal cancer.

Patients who had received prior therapy with bevacizumab or prior systemic anticancer therapy for ovarian cancer (e.g. chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy, or hormonal therapy) or previous radiotherapy to the abdomen or pelvis were excluded from the study.

A total of 1873 patients were randomised in equal proportions to the following three arms:

  • CPP arm: Five cycles of placebo (started cycle 2) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m²) for 6 cycles followed by placebo alone, for a total of up to 15 months of therapy
  • CPB15 arm: Five cycles of Avastin (15 mg/kg q3w started cycle 2) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m²) for 6 cycles followed by placebo alone, for a total of up to 15 months of therapy
  • CPB15+ arm: Five cycles of Avastin (15 mg/kg q3w started cycle 2) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m²) for 6 cycles followed by continued use of Avastin (15 mg/kg q3w) as single agent for a total of up to 15 months of therapy.

The majority of patients included in the study were White (87% in all three arms); the median age was 60 years in CPP and CPB15 arms and 59 years in CPB15+ arm; and 29% of patients in CPP or CPB15 and 26% in CPB15+ were over 65 years of age. Overall approximately 50% of patients had a GOG PS of 0 at baseline, 43% a GOG PS score of 1, and 7% a GOG PS score of 2. Most patients had EOC (82% in CPP and CPB15, 85% in CPB15+) followed by PPC (16% in CPP, 15% in CPB15, 13% in CPB15+) and FTC (1% in CPP, 3% in CPB15, 2% in CPB15+). The majority of patients had serous adenocarcinoma histologic type (85% in CPP and CPB15, 86% in CPB15+). Overall approximately 34% of patients were FIGO Stage III optimally debulked with gross residual disease, 40% Stage III sub-optimally debulked, and 26% were Stage IV patients.

The primary endpoint was PFS based on investigator’s assessment of disease progression based on radiological scans or CA 125 levels, or symptomatic deterioration per protocol. In addition, a prespecified analysis of the data censoring for CA-125 progression events was conducted, as well as an independent review of PFS as determined by radiological scans.

The trial met its primary objective of PFS improvement. Compared to patients treated with chemotherapy (carboplatin and paclitaxel) alone in the front-line setting, patients who received bevacizumab at a dose of 15 mg/kg q3w in combination with chemotherapy and continued to receive bevacizumab alone (CPB15+), had a clinically meaningful and statistically significant improvement in PFS.

In patients who only received bevacizumab in combination with chemotherapy and did not continue to receive bevacizumab alone (CPB15), no clinically meaningful benefit in PFS was observed.

The results of this study are summarised in Table 16.

Table 16. Efficacy results from study GOG-0218:

Progression-free survival1
 CPP (n=625) CPB15 (n=625) CPB15+ (n=623)
Median PFS (months)10.611.614.7
Hazard Ratio (95% CI)2 0.89 (0.78, 1.02) 0.70 (0.61, 0.81)
p-value3,4 0.0437<0.0001
Objective response Rate5
 CPP (n=396) CPB15 (n=393) CPB15+ (n=403)
% pts with objective response63.466.266.0
p-value 0.23410.2041
Overall survival6
 CPP (n=625) CPB15 (n=625) CPB15+ (n=623)
Median OS (months) 40.638.843.8
Hazard Ratio (95% CI)2 1.07 (0.91, 1.25) 0.88 (0.75, 1.04)
p-value3 0.21970.0641

1 Investigator assessed GOG protocol-specified PFS analysis (neither censored for CA-125 progressions nor censored for NPT prior to disease progression) with data cut-off date of 25 February, 2010.
2 Relative to the control arm; stratified hazard ratio.
3 One-sided log-rank p-value
4 Subject to a p-value boundary of 0.0116.
5 Patients with measurable disease at baseline.
6 Final overall survival analysis performed when 46.9% of the patients had died.

Prespecified PFS analyses were conducted, all with a cut-off date of 29 September 2009. The results of these prespecified analyses are as follows:

  • The protocol specified analysis of investigator-assessed PFS (without censoring for CA-125 progression or non-protocol therapy [NPT]) shows a stratified hazard ratio of 0.71 (95% CI: 0.61-0.83, 1-sided log-rank p-value<0.0001) when CPB15+ is compared with CPP, with a median PFS of 10.4 months in the CPP arm and 14.1 months in the CPB15+ arm.
  • The primary analysis of investigator-assessed PFS (censoring for CA-125 progressions and NPT) shows a stratified hazard ratio of 0.62 (95% CI: 0.52-0.75, 1-sided log-rank p-value <0.0001) when CPB15+ is compared with CPP, with a median PFS of 12.0 months in the CPP arm and 18.2 months in the CPB15+ arm.
  • The analysis of PFS as determined by the independent review committee (censoring for NPT) shows a stratified hazard ratio of 0.62 (95% CI: 0.50-0.77, 1-sided log-rank p-value <0.0001) when CPB15+ is compared with CPP, with a median PFS of 13.1 in the CPP arm and 19.1 months in the CPB15+ arm.

PFS subgroup analyses by disease stage and debulking status are summarised in Table 17. These results demonstrate robustness of the analysis of PFS as shown in Table 16.

Table 17. PFS1 results by disease stage and debulking status from study GOG-0218:

Randomised patients stage III optimally debulked disease2,3
 CPP (n=219) CPB15 (n=204) CPB15+ (n=216)
Median PFS (months)4 12.414.317.5
Hazard ratio (95% CI)  0.81 (0.62, 1.05) 0.66 (0.50, 0.86)
Randomised patients with stage III suboptimally debulked disease3
 CPP (n=253) CPB15 (n=256) CPB15+ (n=242)
Median PFS (months) 10.110.913.9
Hazard ratio (95% CI)4  0.93 (0.77, 1.14) 0.78 (0.63, 0.96)
Randomised patients with stage IV disease
 CPP (n=153) CPB15 (n=165) CPB15+ (n=165)
Median PFS (months) 9.510.412.8
Hazard Ratio (95% CI)4  0.90 (0.70, 1.16) 0.64 (0.49, 0.82)

1 Investigator assessed GOG protocol-specified PFS analysis (neither censored for CA-125 progressions nor censored for NPT prior to disease progression) with data cut-off date of 25 February, 2010
2^ With gross residual disease.
3^ 3.7% of the overall randomised patient population had Stage IIIB disease.
4^ Relative to the control arm.

BO17707 (ICON7):

BO17707 was a Phase III, two arm, multicentre, randomised, controlled, open-label study comparing the effect of adding Avastin to carboplatin plus paclitaxel in patients with FIGO stage I or IIA (Grade 3 or clear cell histology only; n=142), or FIGO stage IIB – IV (all Grades and all histological types, n=1386) epithelial ovarian, fallopian tube or primary peritoneal cancer following surgery (NCI – CTCAE v.3). FIGO staging version dated 1988 was used in this trial.

Patients who had received prior therapy with bevacizumab or prior systemic anticancer therapy for ovarian cancer (e.g. chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy, or hormonal therapy) or previous radiotherapy to the abdomen or pelvis were excluded from the study.

A total of 1528 patients were randomised in equal proportions to the following two arms:

  • CP arm: Carboplatin (AUC 6) and paclitaxel (175 mg/m²) for 6 cycles of 3 weeks duration
  • CPB7.5+ arm: Carboplatin (AUC 6) and paclitaxel (175 mg/m²) for 6 cycles of 3 weeks plus Avastin (7.5 mg/kg q3w) for up to 12 months (Avastin was started at cycle 2 of chemotherapy if treatment was initiated within 4 weeks of surgery or at cycle 1 if treatment was initiated more than 4 weeks after surgery).

The majority of patients included in the study were White (96%), the median age was 57 years in both treatment arms, 25% of patients in each treatment arm were 65 years of age or over, and approximately 50% of patients had an ECOG PS of 1; 7% of patients in each treatment arm had an ECOG PS of 2. The majority of patients had EOC (87.7%) followed by PPC (6.9%) and FTC (3.7%) or a mixture of the three origins (1.7%). Most patients were FIGO Stage III (both 68%) followed by FIGO Stage IV (13% and 14%), FIGO Stage II (10% and 11%) and FIGO Stage I (9% and 7%). The majority of the patients in each treatment arm (74% and 71%) had poorly differentiated (Grade 3) primary tumours at baseline. The incidence of each histologic sub-type of EOC was similar between the treatment arms; 69% of patients in each treatment arm had serous adenocarcinoma histologic type.

The primary endpoint was PFS as assessed by the investigator using RECIST.

The trial met its primary objective of PFS improvement. Compared to patients treated with chemotherapy (carboplatin and paclitaxel) alone in the front-line setting, patients who received bevacizumab at a dose of 7.5 mg/kg q3w in combination with chemotherapy and continued to receive bevacizumab for up to 18 cycles had a statistically significant improvement in PFS.

The results of this study are summarised in Table 18.

Table 18. Efficacy results from study BO17707 (ICON7):

Progression-free survival
 CP (n=764) CPB7.5+ (n=764)
Median PFS (months)2 16.919.3
Hazard ratio [95% CI]2 0.86 [0.75; 0.98]
 (p-value=0.0185)
Objective Response Rate1
 CP (n=277)CPB7.5+ (n=272)
Response rate54.9%64.7%
 (p-value=0.0188)
Overall Survival3
 CP (n=764) CPB7.5+ (n=764)
Median (months)58.057.4
Hazard ratio [95% CI] 0.99 [0.85; 1.15]
 (p-value=0. 8910)

1 In patients with measurable disease at baseline.
2 Investigator assessed PFS analysis with data cut-off date of 30 November 2010.
3 Final overall survival analysis performed when 46.7% of the patients had died with data cut-off date of 31 March 2013.

The primary analysis of investigator-assessed PFS with a data cut-off date of 28 February 2010 shows an unstratified hazard ratio of 0.79 (95% CI: 0.68-0.91, 2-sided log-rank p-value 0.0010) with a median PFS of 16.0 months in the CP arm and 18.3 months in the CPB7.5+ arm.

PFS subgroup analyses by disease stage and debulking status are summarised in Table 19. These results demonstrate robustness of the primary analysis of PFS as shown in Table 18.

Table 19. PFS1 results by disease stage and debulking status from study BO17707 (ICON7):

Randomised patients stage III optimally debulked disease2,3
 CP (n=368) CPB7.5+ (n=383)
Median PFS (months)17.719.3
Hazard ratio (95% CI)4  0.89 (0.74, 1.07)
Randomised patients with stage III suboptimally debulked disease3
 CP (n=154) CPB7.5+ (n=140)
Median PFS (months) 10.116.9
Hazard ratio (95% CI)4  0.67 (0.52, 0.87)
Randomised patients with stage IV disease
 CP (n=97) CPB7.5+ (n=104)
Median PFS (months) 10.113.5
Hazard Ratio (95% CI)4 0.74 (0.55, 1.01)

1 Investigator assessed PFS analysis with data cut-off date of 30 November 2010.
2 With or without gross residual disease.
3 5.8% of the overall randomised patient population had Stage IIIB disease.
4 Relative to the control arm.

Recurrent ovarian cancer

The safety and efficacy of Avastin in the treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer was studied in three phase III trials (AVF4095g , MO22224 and GOG-0213) with different patient populations and chemotherapy regimens.

  • AVF4095g evaluated the efficacy and safety of bevacizumab in combination with carboplatin and gemcitabine, followed by bevacizumab as a single agent in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
  • GOG-0213 evaluated the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel, followed by bevacizumab as a single agent in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
  • MO22224 evaluated the efficacy and safety of bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

AVF4095g:

The safety and efficacy of Avastin in the treatment of patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who have not received prior chemotherapy in the recurrent setting or prior bevacizumab treatment, was studied in a phase III randomised, double-blind, placebo-controlled trial (AVF4095g). The study compared the effect of adding Avastin to carboplatin and gemcitabine chemotherapy and continuing Avastin as a single agent to progression, to carboplatin and gemcitabine alone.

Only patients with histologically documented ovarian, primary peritoneal, or fallopian tube carcinoma that had recurred > 6 months after platinum-based chemotherapy and who had not received chemotherapy in the recurrent setting and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents were included in the study.

A total of 484 patients with measurable disease were randomised 1:1 to either:

  • Carboplatin (AUC4, Day 1) and gemcitabine (1000 mg/m² on Days 1 and 8) and concurrent placebo every 3 weeks for 6 and up to 10 cycles followed by placebo (every 3 weeks) alone until disease progression or unacceptable toxicity
  • Carboplatin (AUC4, Day 1) and gemcitabine (1000 mg/m² on Days 1 and 8) and concurrent Avastin (15 mg/kg Day 1) every 3 weeks for 6 and up to 10 cycles followed by Avastin (15 mg/kg every 3 weeks) alone until disease progression or unacceptable toxicity

The primary endpoint was progression-free survival based on investigator assessment using modified RECIST 1.0. Additional endpoints included objective response, duration of response, overall survival and safety. An independent review of the primary endpoint was also conducted.

The results of this study are summarised in Table 20.

Table 20. Efficacy results from study AVF4095g:

Progression-free survival
 Investigator AssessmentIRC Assessment
 Placebo + C/G (n=242) Avastin + C/G (n=242) Placebo + C/G (n=242) Avastin + C/G (n=242)
Not censored for NPT
Median PFS (months) 8.412.48.612.3
Hazard ratio (95% CI) 0.524 [0.425, 0.645] 0.480 [0.377, 0.613]
p–value<0.0001<0.0001
Censored for NPT
Median PFS (months) 8.412.48.612.3
Hazard ratio (95% CI) 0.484 [0.388, 0.605] 0.451 [0.351, 0.580]
p –value<0.0001<0.0001
Objective response rate
 Placebo + C/G (n=242) Avastin + C/G (n=242)
Median OS (months)32.933.6
Hazard Ratio (95% CI) 0.952 [0.771, 1.176]
p-value0.6479

PFS subgroup analyses depending on recurrence since last platinum therapy are summarised in Table 21.

Table 21. Progression-free survival by time from last platinum therapy to recurrence:

 Investigator Assessment
Time from last platinum therapy to recurrencePlacebo + C/G (n=242) Avastin + C/G (n=242)
6-12 months (n=202)
Median8.011.9
Hazard ratio (95% CI)0.41 (0.29-0.58)
>12 months (n=282)
Median9.712.4
Hazard ratio (95% CI) 0.55 (0.41–0.73)

GOG-0213:

GOG-0213, a phase III randomized controlled open label trial, studied the safety and efficacy of Avastin in the treatment of patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who have not received prior chemotherapy in the recurrent setting. There was no exclusion criterion for prior anti-angiogenic therapy. The study evaluated the effect of adding Avastin to carboplatin+paclitaxel and continuing Avastin as a single agent until disease progression or unacceptable toxicity compared to carboplatin+paclitaxel alone.

A total of 673 patients were randomized in equal proportions to the following two treatment arms:

  • CP arm: Carboplatin (AUC5) and paclitaxel (175 mg/m² IV) every 3 weeks for 6 and up to 8 cycles.
  • CPB arm: Carboplatin (AUC5) and paclitaxel (175 mg/m² IV) and concurrent Avastin (15 mg/kg) every 3 weeks for 6 and up to 8 cycles, followed by Avastin (15 mg/kg every 3 weeks) alone until disease progression or unacceptable toxicity.

Most patients in both the CP arm (80.4%) and the CPB arm (78.9%) were White. The median age was 60.0 years in the CP arm and 59.0 years in the CPB arm. The majority of patients (CP: 64.6%; CPB: 68.8%) were in the age category <65 years. At baseline, most patients in both treatment arms had a GOG PS of 0 (CP: 82.4%: CPB; 80.7%) or 1 (CP: 16.7%: CPB; 18.1%). A GOG PS of 2 at baseline was reported in 0.9% of patients in the CP arm and in 1.2% of patients in the CPB arm."

The primary efficacy endpoint was overall survival (OS). The main secondary efficacy endpoint was progression-free survival (PFS).Results are presented in Table 22.

Table 22. Efficacy results1,2 from study GOG-0213:

Primary Endpoint
Overall Survival (OS) CP (n=336) CPB (n=337)
Median OS (months) 37.342.6
Hazard ratio (95% CI) (eCRF)a0.823 [CI: 0.680, 0.996]
p-Value0.0447
Hazard ratio (95% CI) (registration form)b0.838 [CI: 0.693, 1.014]
p-Value0.0683
Secondary Endpoint
Progression-free survival (PFS)CP (n=336) CPB (n=337)
Median PFS (months) 10.213.8
Hazard ratio (95% CI) 0.613 [CI: 0.521, 0.721]
p-value<0.0001

1 Final Analysis 2 Tumour assessments and response evaluations were determined by the investigators using the GOG RECIST criteria (Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228Y247).
a Hazard ratio was estimated from Cox proportional hazards models stratified by the duration of platinum free-interval prior to enrolling onto this study per eCRF (electronic case report form) and secondary surgical debulking status Yes/No (Yes=randomized to undergo cytoreduction or randomized to not undergo cytoreduction; No= not a candidate or did not consent to cytoreduction).
b stratified by the duration of treatment free-interval prior to enrolling onto this study per the registration form, and secondary surgical debulking status Yes/No.

The trial met its primary objective of OS improvement. Treatment with Avastin at 15 mg/kg every 3 weeks in combination with chemotherapy (carboplatin and paclitaxel) for 6 and up to 8 cycles, followed by Avastin until disease progression or unacceptable toxicity resulted, when data were derived from eCRF, in a clinically meaningful and statistically significant improvement in OS compared to treatment with carboplatin and paclitaxel alone.

MO22224:

Study MO22224 evaluated the efficacy and safety of bevacizumab in combination with chemotherapy for platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. This study was designed as an open-label, randomized, two-arm Phase III evaluation of bevacizumab plus chemotherapy (CT+BV) versus chemotherapy alone (CT).

A total of 361 patients were enrolled into this study and administered either chemotherapy (paclitaxel, topotecan, or pegylated liposomal doxorubicin (PLD) alone or in combination with bevacizumab:

  • CT Arm (chemotherapy alone):
    • Paclitaxel 80 mg/m² as a 1-hour IV infusion on Days 1, 8, 15, and 22 every 4 weeks.
    • Topotecan 4 mg/m² as a 30-minute IV infusion on Days 1, 8, and 15 every 4 weeks. Alternatively, a 1.25 mg/m 2 dose could be administered over 30 minutes on Days 1–5 every 3 weeks.
    • PLD 40 mg/m² as a 1 mg/min IV infusion on Day 1 only every 4 weeks. After Cycle 1, the drug could be delivered as a 1-hour infusion.
  • CT+BV Arm (chemotherapy plus bevacizumab):
    • The chosen chemotherapy was combined with bevacizumab 10 mg/kg IV every 2 weeks (or bevacizumab 15 mg/kg every 3 weeks if used in combination with topotecan 1.25 mg/m² on Days 1–5 every 3 weeks).

Eligible patients had epithelial ovarian, fallopian tube or primary peritoneal cancer that progressed within <6 months of previous platinum therapy consisting of a minimum of 4 platinum therapy cycles. Patients should have had a life expectancy of ≥12 weeks and no prior radiotherapy to the pelvis or abdomen. Most patients were FIGO Stage IIIC or Stage IV. The majority of patients in both arms had an ECOG Performance Status (PS) of 0 (CT: 56.4% vs. CT + BV: 61.2%). The percentage of patients with an ECOG PS of 1 or ≥2 was 38.7% and 5.0% in the CT arm, and 29.8% and 9.0% in the CT + BV arm. Information on race exists for 29.3% of patients and nearly all patients were white. The median age of patients was 61.0 (range: 25−84) years. A total of 16 patients (4.4%) were >75 years old. The overall rates of discontinuation due to adverse events were 8.8% in the CT arm and 43.6% in the CT + BV arm (mostly due to Grade 2-3 adverse events) and the median time to discontinuation in the CT + BV arm was 5.2 months compared with 2.4 months in the CT arm. The rates of discontinuation due to adverse events in the subgroup of patients >65 years old were 8.8% in the CT arm and 50.0% in the CT + BV arm. The HR for PFS was 0.47 (95% CI: 0.35, 0.62) and 0.45 (95% CI: 0.31, 0.67) for the <65 and ≥65 subgroups, respectively.

The primary endpoint was progression-free-survival, with secondary endpoints including objective response rate and overall survival. Results are presented in Table 23.

Table 23. Efficacy Results from Study MO22224:

Primary Endpoint
Progression-Free Survival*
 CT (n=182) CT+BV (n=179)
Median (months) 3.46.7
Hazard ratio (95% CI) 0.379 [0.296, 0.485]
p-value<0.0001
Secondary Endpoints
Objective Response Rate**
 CT (n=144) CT+BV (n=142)
% patients with objective response18 (12.5%) 40 (28.2%)
p–value0.0007
Overall Survival (final analysis)***
 CT (n=182) CT+BV (n=179)
Median OS (months) 13.316.6
Hazard Ratio (95% CI) 0.870 [0.678, 1.116]
p-value0.2711

All analyses presented in this table are stratified analyses.
* Primary analysis was performed with a data cut-off date of 14 November 2011.
** Randomized Patients with Measurable Disease at Baseline.
*** The final analysis of overall survival was performed when 266 deaths, which account for 73.7% of enrolled patients, were observed.

The trial met its primary objective of PFS improvement. Compared to patients treated with chemotherapy (paclitaxel, topotecan or PLD) alone in the recurrent platinum-resistant setting, patients who received bevacizumab at a dose of 10 mg/kg every 2 weeks (or 15 mg/kg every 3 weeks if used in combination with 1.25 mg/m² topotecan on Days 1–5 every 3 weeks) in combination with chemotherapy and continued to receive bevacizumab until disease progression or unacceptable toxicity, had a statistically significant improvement in PFS. The exploratory PFS and OS analyses by chemotherapy cohort (paclitaxel, topotecan and PLD) are summarized in Table 24.

Table 24. Exploratory PFS and OS analyses by chemotherapy cohort:

 CTCT+BV
Paclitaxeln=115
Median PFS (months) 3.99.2
Hazard ratio (95% CI) 0.47 [0.31, 0.72]
Median OS (months) 13.222.4
Hazard ratio (95% CI) 0.64 [0.41, 0.99]
Topotecann=120
Median PFS (months) 2.16.2
Hazard ratio (95% CI) 0.28 [0.18, 0.44]
Median OS (months) 13.313.8
Hazard ratio (95% CI) 1.07 [0.70, 1.63]
PLDn=126
Median PFS (months) 3.55.1
Hazard ratio (95% CI) 0.53 [0.36, 0.77]
Median OS (months) 14.113.7
Hazard ratio (95% CI) 0.91 [0.61, 1.35]

Cervical Cancer

GOG-0240:

The efficacy and safety of Avastin in combination with chemotherapy (paclitaxel and cisplatin or paclitaxel and topotecan) in the treatment for patients with persistent, recurrent or metastatic carcinoma of the cervix was evaluated in study GOG-0240, a randomised, four-arm, open label, multi- centre phase III trial.

A total of 452 patients were randomised to receive either:

  • Paclitaxel 135 mg/m² IV over 24 hours on Day 1 and cisplatin 50 mg/m² IV on Day 2, every 3 weeks (q3w); or Paclitaxel 175 mg/m² IV over 3 hours on Day 1 and cisplatin 50 mg/m² IV on Day 2 (q3w); or Paclitaxel 175 mg/m² IV over 3 hours on Day 1 and cisplatin 50 mg/m² IV on Day 1 (q3w)
  • Paclitaxel 135 mg/m² IV over 24 hours on Day 1 and cisplatin 50 mg/m² IV on Day 2 plus bevacizumab 15 mg/kg IV on Day 2 (q3w); or Paclitaxel 175 mg/m² IV over 3 hours on Day 1 and cisplatin 50 mg/m² IV on Day 2 plus bevacizumab 15 mg/kg IV on Day 2 (q3w); or Paclitaxel 175 mg/m² IV over 3 hours on Day 1 and cisplatin 50 mg/m² IV on Day 1 plus bevacizumab 15 mg/kg IV on Day 1 (q3w)
  • Paclitaxel 175 mg/m² IV over 3 hours on Day 1 and topotecan 0.75 mg/m² IV over 30 minutes on days 1-3 (q3w)
  • Paclitaxel 175 mg/m² IV over 3 hours on Day 1 and topotecan 0.75 mg/m² IV over 30 minutes on Days 1-3 plus bevacizumab 15 mg/kg IV on Day 1 (q3w)

Eligible patients had persistent, recurrent or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which was not amenable to curative treatment with surgery and/or radiation therapy and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.

The median age was 46.0 years (range: 20−83) in the Chemo alone group and 48.0 years (range: 22−85) in the Chemo+Avastin group; with 9.3% of patients in the Chemo alone group and 7.5% of patients in the Chemo+Avastin group over the age of 65 years. Of the 452 patients randomized at baseline, the majority of patients were white (80.0% in the Chemo alone group and 75.3% in the Chemo+Avastin group), had squamous cell carcinoma (67.1% in the Chemo alone group and 69.6% in the Chemo+Avastin group), had persistent/recurrent disease (83.6% in the Chemo alone group and 82.8% in the Chemo+Avastin group), had 1-2 metastatic sites (72.0% in the Chemo alone group and 76.2% in the Chemo+Avastin group), had lymph node involvement (50.2% in the Chemo alone group and 56.4% in the Chemo+Avastin group), and had a platinum free interval ≥6 months (72.5% in the Chemo alone group and 64.4% in the Chemo+Avastin group).

The primary efficacy endpoint was overall survival. Secondary efficacy endpoints included progression-free survival and objective response rate. Results from the primary analysis and the follow-up analysis are presented by Avastin Treatment and by Trial Treatment in Table 25 and Table 26, respectively.

Table 25. Efficacy results from study GOG-0240 by Avastin Treatment:

 Chemotherapy (n=225) Chemotherapy + Avastin (n=227)
Primary Endpoint
Overall Survival – Primary analysis6
Median (months)112.916.8
Hazard ratio [95% CI] 0.74 [0.58, 0.94] (p-value5 = 0.0132)
Overall Survival – Follow-up analysis7
Median (months)113.316.8
Hazard ratio [95% CI] 0.76 [0.62, 0.94] (p-value5,8 = 0.0126)
Secondary Endpoints
Progression-free survival – Primary analysis6
Median PFS (months)16.08.3
Hazard ratio [95% CI] 0.66 [0.54, 0.81] (p-value5 <0.0001)
Best Overall Response – Primary analysis6
Responders (Response rate2) 76 (33.8%) 103 (45.4%)
95% CI for Response Rates3[27.6%, 40.4%] [38.8%, 52.1%]
Difference in Response Rates11.60%
95% CI for Difference in Response Rates4[2.4%, 20.8%]
p-value (Chi-squared Test) 0.0117

1 Kaplan-Meier estimates
2 Patients and percentage of patients with best overall response of confirmed CR or PR; percentage calculated on patients with measurable disease at baseline
3 95% CI for one sample binomial using Pearson-Clopper method
4 Approximate 95% CI for difference of two rates using Hauck-Anderson method
5 log-rank test (stratified)
6 Primary analysis was performed with a data cut-off date of 12 December 2012 and is considered the final analysis
7 Follow-up analysis was performed with a data cut-off date of 07 March 2014
8 p-value displayed for descriptive purpose only

Table 26. Overall survival results from study GOG-0240 by Trial Treatment:

Paediatric population

The European Medicines Agency has waived the obligation to submit the results of studies, in all subsets of the paediatric population, in breast carcinoma, adenocarcinoma of the colon and rectum, lung carcinoma (small cell and non-small cell carcinoma), kidney and renal pelvis carcinoma (excluding nephroblastoma, nephroblastomatosis, clear cell sarcoma, mesoblastic nephroma, renal medullary carcinoma and rhabdoid tumour of the kidney), ovarian carcinoma (excluding rhabdomyosarcoma and germ cell tumours), fallopian tube carcinoma (excluding rhabdomyosarcoma and germ cell tumours), peritoneal carcinoma (excluding blastomas and sarcomas) and cervix and corpus uteri carcinoma.

High-grade glioma

Anti-tumour activity was not observed in two earlier studies among a total of 30 children aged >3 years old with relapsed or progressive high-grade glioma when treated with bevacizumab and irinotecan (CPT-11). There is insufficient information to determine the safety and efficacy of bevacizumab in children with newly-diagnosed high-grade glioma.

  • In a single-arm study (PBTC-022), 18 children with recurrent or progressive non-pontine high-grade glioma (including 8 with glioblastoma [WHO Grade IV], 9 with anaplastic astrocytoma [Grade III] and 1 with anaplastic oligodendroglioma [Grade III]) were treated with bevacizumab (10 mg/kg) two weeks apart and then with bevacizumab in combination with CPT-11 (125-350 mg/m²) once every two weeks until progression. There were no objective (partial or complete) radiological responses (MacDonald criteria). Toxicity and adverse reactions included arterial hypertension and fatigue as well as CNS ischaemia with acute neurological deficit.
  • In a retrospective single institution series, 12 consecutive (2005 to 2008) children with relapsed or progressive high-grade glioma (3 with WHO Grade IV, 9 with Grade III) were treated with bevacizumab (10 mg/kg) and irinotecan (125 mg/m²) every 2 weeks. There were no complete responses and 2 partial responses (MacDonald criteria).

In a randomized phase II study (BO25041) a total of 121 patients aged ≥3 years to <18 years with newly diagnosed supratentorial or infratentorial cerebellar or peduncular high-grade glioma (HGG) were treated with post operative radiation therapy (RT) and adjuvant temozolomide (T) with and without bevacizumab: 10 mg/kg every 2 weeks IV.

The study did not meet its primary endpoint of demonstrating a significant improvement of EFS (Central Radiology Review Committee (CRRC)-assessed) when bevacizumab was added to the RT/T arm compared with RT/T alone (HR = 1.44; 95% CI: 0.90, 2.30). These results were consistent with those from various sensitivity analyses and in clinically relevant subgroups. The results for all secondary endpoints (investigator assessed EFS, and ORR and OS) were consistent in showing no improvement associated with the addition of bevacizumab to the RT/T arm compared with the RT/T arm alone.

Addition of Avastin to RT/T did not demonstrate clinical benefit in study BO25041 in 60 evaluable children patients with newly diagnosed supratentorial or infratentorial cerebellar or peduncular high- grade glioma (HGG) (See section 4.2 for information on paediatric use).

Soft tissue sarcoma

In a randomized phase II study (BO20924) a total of 154 patients aged ≥6 months to <18 years with newly diagnosed metastatic rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma were treated with standard of care (Induction IVADO/IVA+/- local therapy followed by Maintenance Vinorelbine and cyclophosphamide) with or without bevacizumab (2.5 mg/kg/week) for a total duration of treatment of approximately 18 months. At the time of the final primary analysis, the primary endpoint of EFS by independent central review did not show a statistically significant difference between the two treatment arms, with HR of 0.93 (95% CI: 0.61, 1.41; p-value=0.72).

The difference in ORR per independent central review was 18% (CI: 0.6%, 35.3%) between the two treatment arms in the few patients who had evaluable tumor at baseline and had a confirmed response prior to receiving any local therapy: 27/75 patients (36.0%, 95% CI: 25.2%, 47.9%) in the Chemo arm and 34/63 patients (54.0%, 95% CI: 40.9%, 66.6%) in the Bv + Chemo arm. The secondary endpoint of Overall Survival (OS) was not mature . Until mature OS results and safety data are available no definitive conclusion can be drawn on the benefit/risk balance.

Addition of Avastin to standard of care did not demonstrate clinical benefit in clinical trial BO20924, in 71 evaluable children (from age 6 months to less than 18 years old) patients with metastatic Rhabdomyosarcoma and non-Rhabdomyosarcoma Soft Tissue Sarcoma. (See section 4.2 for information on paediatric use).

The incidence of AEs, including Grade ≥3 AEs and SAEs, was similar between the two treatment arms. No AEs leading to death occurred in either treatment arm; all deaths were attributed to disease progression. Bevacizumab addition to multimodal standard of care treatment seemed to be tolerated in this paediatric population.

Pharmacokinetic properties

The pharmacokinetic data for bevacizumab are available from ten clinical trials in patients with solid tumours. In all clinical trials, bevacizumab was administered as an IV infusion. The rate of infusion was based on tolerability, with an initial infusion duration of 90 minutes. The pharmacokinetics of bevacizumab was linear at doses ranging from 1 to 10 mg/kg.

Distribution

The typical value for central volume (Vc) was 2.73 L and 3.28 L for female and male patients respectively, which is in the range that has been described for IgGs and other monoclonal antibodies.

The typical value for peripheral volume (Vp) was 1.69 L and 2.35 L for female and male patients respectively, when bevacizumab is co-administered with anti-neoplastic agents. After correcting for body weight, male patients had a larger Vc (+ 20%) than female patients.

Biotransformation

Assessment of bevacizumab metabolism in rabbits following a single IV dose of 125I-bevacizumab indicated that its metabolic profile was similar to that expected for a native IgG molecule which does not bind VEGF. The metabolism and elimination of bevacizumab is similar to endogenous IgG i.e. primarily via proteolytic catabolism throughout the body, including endothelial cells, and does not rely primarily on elimination through the kidneys and liver. Binding of the IgG to the FcRn receptor results in protection from cellular metabolism and the long terminal half-life.

Elimination

The value for clearance is, on average, equal to 0.188 and 0.220 L/day for female and male patients, respectively. After correcting for body weight, male patients had a higher bevacizumab clearance (+ 17%) than females. According to the two-compartmental model, the elimination half-life is 18 days for a typical female patient and 20 days for a typical male patient.

Low albumin and high tumour burden are generally indicative of disease severity. Bevacizumab clearance was approximately 30% faster in patients with low levels of serum albumin and 7% faster in subjects with higher tumour burden when compared with a typical patient with median values of albumin and tumour burden.

Pharmacokinetics in special populations

The population pharmacokinetics were analysed in adult and pediatric patients to evaluate the effects of demographic characteristics. In adults, the results showed no significant difference in the pharmacokinetics of bevacizumab in relation to age.

Renal impairment

No trials have been conducted to investigate the pharmacokinetics of bevacizumab in renally impaired patients since the kidneys are not a major organ for bevacizumab metabolism or excretion.

Hepatic impairment

No trials have been conducted to investigate the pharmacokinetics of bevacizumab in patients with hepatic impairment since the liver is not a major organ for bevacizumab metabolism or excretion.

Paediatric population

The pharmacokinetics of bevacizumab were evaluated in 152 children, adolescents and young adults (7 months to 21 years, 5.9 to 125 kg) across 4 clinical studies using a population pharmacokinetic model. The pharmacokinetic results show that the clearance and volume of distribution of bevacizumab were comparable between paediatric and young adult patients when normalised by body weight, with exposure trending lower as body weight decreased. Age was not associated with the pharmacokinetics of bevacizumab when body weight was taken into account.

The pharmacokinetics of bevacizumab was well characterized by the paediatric population PK model for 70 patients in Study BO20924 ((1.4 to 17.6 years; 11.6 to 77.5 kg) and 59 patients in Study BO25041 (1 to 17 years; 11.2 to 82.3 kg). In Study BO20924, bevacizumab exposure was generally lower compared to a typical adult patient at the same dose. In Study BO25041, bevacizumab exposure was similar compared to a typical adult at the same dose. In both studies, bevacizumb exposure trended lower as body weight decreased.

Preclinical safety data

In studies of up to 26 weeks duration in cynomolgus monkeys, physeal dysplasia was observed in young animals with open growth plates, at bevacizumab average serum concentrations below the expected human therapeutic average serum concentrations. In rabbits, bevacizumab was shown to inhibit wound healing at doses below the proposed clinical dose. Effects on wound healing were shown to be fully reversible.

Studies to evaluate the mutagenic and carcinogenic potential of bevacizumab have not been performed.

No specific studies in animals have been conducted to evaluate the effect on fertility. An adverse effect on female fertility can however be expected as repeat dose toxicity studies in animals have shown inhibition of the maturation of ovarian follicles and a decrease/absence of corpora lutea and associated decrease in ovarian and uterus weight as well as a decrease in the number of menstrual cycles.

Bevacizumab has been shown to be embryotoxic and teratogenic when administered to rabbits. Observed effects included decreases in maternal and foetal body weights, an increased number of foetal resorptions and an increased incidence of specific gross and skeletal foetal malformations. Adverse foetal outcomes were observed at all tested doses, of which the lowest dose resulted in average serum concentrations approximately 3 times larger than in humans receiving 5 mg/kg every 2 weeks. Information on foetal malformations observed in the post marketing setting are provided in section 4.6 Fertility, Pregnancy and Lactation and 4.8 Undesirable Effects.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.